Phase 3 clinical trial results have demonstrated that the dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist muraglitazar achieves significant beneficial lipid effects compared with pioglitazone, and the agent also provides long-term glycemic control in type 2 diabetics. The results were reported during the American Diabetes Association (ADA) 65th Annual Meeting in San Diego, Calif.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Dual peroxisome proliferator-activated receptor agonist demonstrates significant lipid benefits

Newsletter